Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1998 1
2000 1
2003 1
2005 2
2007 1
2008 1
2009 1
2010 2
2013 1
2014 2
2015 2
2017 5
2018 3
2019 2
2020 1
2021 3
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Galiè N, et al. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Circulation. 2009. PMID: 19470885 Clinical Trial.
Changes in World Health Organization functional class, clinical worsening, and health-related quality of life were also assessed. Patients completing the 16-week study could enter a long-term extension study. Tadalafil increased the distance walked in 6 minutes in a dose-d …
Changes in World Health Organization functional class, clinical worsening, and health-related quality of life were also assessed. Patients c …
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. ...The primary end point in a time-to-event analysis was the first event of clinical failure, whi …
BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with p …
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.
Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, Beurnier A, Bourdin A, Bouvaist H, Bulifon S, Chabanne C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, Favrolt N, Feng Y, Horeau-Langlard D, Jevnikar M, Jutant EM, Liang Z, Magro P, Mauran P, Moceri P, Mornex JF, Palat S, Parent F, Picard F, Pichon J, Poubeau P, Prévot G, Renard S, Reynaud-Gaubert M, Riou M, Roblot P, Sanchez O, Seferian A, Tromeur C, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O. Boucly A, et al. Among authors: reynaud gaubert m. Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. doi: 10.1164/rccm.202009-3698OC. Am J Respir Crit Care Med. 2021. PMID: 34185620 Free article.
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. ...
Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. …
Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension.
Mismetti V, Delavenne X, Montani D, Bezzeghoud S, Delezay O, Hodin S, Launay D, Marchand-Adam S, Nunes H, Ollier E, Reynaud-Gaubert M, Pastre J, Traclet J, Quetant S, Zeghmar S, Bertoletti L, Cottin V. Mismetti V, et al. Among authors: reynaud gaubert m. Respir Res. 2023 Nov 7;24(1):273. doi: 10.1186/s12931-023-02578-0. Respir Res. 2023. PMID: 37936223 Free PMC article.
An untargeted proteomic analysis using mass spectrometry was performed to identify plasma protein changes associated with long-term overall survival in patients with SSc-PH-ILD. RESULTS: Thirty two patients were included in the analysis, of whom 13 died during follow-up (m …
An untargeted proteomic analysis using mass spectrometry was performed to identify plasma protein changes associated with long-term o …
[Updated indications and contraindications in 2022 for lung transplantation in France].
Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Le Guen M, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M. Le Pavec J, et al. Among authors: reynaud gaubert m. Rev Mal Respir. 2022 Dec;39(10):855-872. doi: 10.1016/j.rmr.2022.10.005. Epub 2022 Nov 10. Rev Mal Respir. 2022. PMID: 36372607 Review. French.
Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and multifaceted attempts have been made to meet the challenges raised by surgical management, perioperative care, and long-term medical com …
Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and mul …
Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome.
Danger R, Royer PJ, Reboulleau D, Durand E, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Gomez C, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Dahan M, Knoop C, Botturi K, Foureau A, Pison C, Koutsokera A, Nicod LP, Brouard S, Magnan A; COLT and SysCLAD Consortia. Danger R, et al. Among authors: reynaud gaubert m. Front Immunol. 2018 Jan 11;8:1841. doi: 10.3389/fimmu.2017.01841. eCollection 2017. Front Immunol. 2018. PMID: 29375549 Free PMC article.
Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunction, leads to poor long-term survival after lung transplantation. Identifying predictors of BOS is essential to prevent the progression of dysfunction before irreversible dama …
Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunction, leads to poor long-term surviv …
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
Martin C, Reynaud-Gaubert M, Hamidfar R, Durieu I, Murris-Espin M, Danner-Boucher I, Chiron R, Leroy S, Douvry B, Grenet D, Mely L, Ramel S, Montcouquiol S, Lemonnier L, Burnet E, Paillasseur JL, Da Silva J, Burgel PR. Martin C, et al. Among authors: reynaud gaubert m. J Cyst Fibros. 2022 May;21(3):489-496. doi: 10.1016/j.jcf.2022.01.012. Epub 2022 Feb 2. J Cyst Fibros. 2022. PMID: 35123901
BACKGROUND: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary disease, often leading to suspend the indication for lung transplantation. Yet no long-term data is available in lung transplant can …
BACKGROUND: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary …
Lung transplantation for sarcoidosis: outcome and prognostic factors.
Le Pavec J, Valeyre D, Gazengel P, Holm AM, Schultz HH, Perch M, Le Borgne A, Reynaud-Gaubert M, Knoop C, Godinas L, Hirschi S, Bunel V, Laporta R, Harari S, Blanchard E, Magnusson JM, Tissot A, Mornex JF, Picard C, Savale L, Bernaudin JF, Brillet PY, Nunes H, Humbert M, Fadel E, Gottlieb J. Le Pavec J, et al. Among authors: reynaud gaubert m. Eur Respir J. 2021 Aug 5;58(2):2003358. doi: 10.1183/13993003.03358-2020. Print 2021 Aug. Eur Respir J. 2021. PMID: 33479107 Free article.
Pulmonary fibrosis predominating peripherally was associated with short-term complications. ANSWER TO THE STUDY QUESTION: Post-transplant survival in patients with pulmonary sarcoidosis was similar to that in patients with other indications for lung transplantation. ...
Pulmonary fibrosis predominating peripherally was associated with short-term complications. ANSWER TO THE STUDY QUESTION: Post-transp …
2022 Update of indications and contraindications for lung transplantation in France.
Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Guen ML, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M. Le Pavec J, et al. Among authors: reynaud gaubert m. Respir Med Res. 2023 Jun;83:100981. doi: 10.1016/j.resmer.2022.100981. Epub 2022 Nov 28. Respir Med Res. 2023. PMID: 36565563
The considerable developments have been driven over the years by indefatigable work conducted at LTx centers to improve donor and recipient selection, combined with multifaceted efforts to overcome challenges raised by the surgical procedure, perioperative care, and long-term …
The considerable developments have been driven over the years by indefatigable work conducted at LTx centers to improve donor and recipient …
Severe pulmonary hypertension associated with COPD: long-term results of a prospective French multicentre cohort.
Dauriat G, Reynaud-Gaubert M, Cottin V, Lamia B, Montani D, Belhadi D, Humbert M, Laouenan C, Mal H; French group of investigators on severe PH-COPD. Dauriat G, et al. Among authors: reynaud gaubert m. Eur Respir J. 2022 Jul 7;60(1):2102897. doi: 10.1183/13993003.02897-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 35595319 Free article. No abstract available.
36 results